Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules

Journal of Immunology

Volumn 160, Issue 9, 1998, Pages 4386-4397

  Fridkis Hareli, Masha ^a   Strominger, Jack L ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID; COPOLYMER; GLUTAMIC ACID; HLA ANTIGEN; HLA DR ANTIGEN; LYSINE; PEPTIDE; POLYPEPTIDE; SUPERANTIGEN; TYROSINE;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MULTIPLE SCLEROSIS; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; TEMPERATURE DEPENDENCE;

B-LYMPHOCYTES; CELL LINE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HLA-DR ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; PEPTIDES; PROTEIN BINDING;

EID: 0032080646     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Rothbard, J. B., and M. L. Gefter. 1991. Interactions between immunogenic peptides and MHC proteins. Anna. Rev. Immunol. 9:527.
2. Bjorkman, P. J., M. A. Saper, B. Samraouri, W. S. Bennet, J. L. Strominger, and D. C. Wiley. 1987. Structure of the human class I histocompatibility antigen. HLA-A2. Nature 329:506.
3. Madden, D. R., J. C. Gorga, J. L. Strominger, and D. C. Wiley. 1991. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature 353:321.
4. Brown, J. H., T. S. Jardetzky, J. C. Gorga, L. J. Stern, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1993. Three dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364:33.
5. Stern, L. J., J. H. Brown, T. S. Jardetzky, J. C. Gorga, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368: 215.
6. b molecule. Nature 348:213.
7. Falk, K., O. Rotzschke, S. Stevanovic, G. Jung, and H.-G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290.
8. Jardetzky, T. S., W. S. Lane, R. A. Robinson, D. R. Madden, and D. C. Wiley. 1991. Identification of self peptides bound to purified HLA-B27. Nature 353:326.
9. Hunt, D. F., R. A. Henderson, J. Shabanowicz, K. Sakaguchi, H. Michel, N. Sevilir, A. Cox, E. Appella, and V. H. Engelhard. 1992. Characterization of peptides bound to class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255:1261.
10. Rudensky, A. Y., P. Preston-Hurlburt, S.-C. Hong, A. Barlow, and C. A. Janeway. 1991. Sequence analysis of peptides bound to MHC class II molecules. Nature 353:622.
11. Chicz, R. M., R. G. Urban, W. S. Lane, J. C. Gorga, L. J. Stern, D. A. A. Vignali, and J. L. Strominger. 1992. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 358:764.
12. Chicz, R. M., R. G. Urban, J. C. Gorga, D. A. A. Vignali, W. S. Lane, and J. L. Strominger. 1993. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178:27.
13. Jardetzky, T. S., J. C. Gorga, R. Bush, J. Rothbard, J. L. Strominger, and D. C. Wiley. 1990. Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding. EMBO J. 9:1797.
14. O'Sullivan, D., T. Arrhenius, J. Sidney, M.-F. Del Guercio, M. Albertson, M. Wall, C. Oseroff, S. Southwood, S. M. Colon, F. C. A. Gaeta, and A. Sette. 1991. On the interaction of promiscuous antigenic peptides with ditferent DR alleles. J. Immunol. 147:2663.
15. Rudensky, A. Y., P. Preston-Hurlburt, B. K. Al-Ramadi, J. Rothbard, and C. A. Janeway. 1992. Truncation variants of peptides isolated from MHC class II molecules suggest sequence motifs. Nature 359:429.
16. Malcherec, G., K. Falk, O. Rotzschke, H.-G. Rammensee, S. Stevanovic, V. Gnau, G. Jung, and A. Melms. 1993. Natural peptide ligand motifs of two HLA molecules associated with myasthenia gravis. Int. Immunol. 5:1229.
17. Falk, K., O. Rotzschke, S. Stevanovic, G. Jung, and H.-G. Rammensee. 1994. Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics 39:230.
18. Teitelbaum, D., A. Meshorer, T. Hirshfeld, R. Arnon, and M. Sela. 1971. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1:242.
19. Teitelbaum, D., C. Webb, A. Meshorer, R. Arnon, and M. Sela. 1973. Suppression by several polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur. J. Immunol. 3:273.
20. Teitelbaum, D., C. Webb, M. Bree, A. Meshorer, R. Arnon, and M. Sela. 1974. Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Clin. Immunol. Immunopathol. 3:256.
21. Lando, Z., D. Teitelbaum, and R. Arnon. 1979. Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to experimental allergic encephalomyelitis. J. Immunol. 123:2156.
22. Sela, M., R. Arnon, and D. Teitelbaum. 1990. Suppressive activity of Cop 1 in EAE and its relevance to multiple sclerosis. Bull. Inst. Pasteur 88:303.
23. Bornstein, M. B., A. Miller, S. Slagle, M. Weitzman, H. Crystal, E. Drexler, M. Keilson, A. Merriam, S. Wassertheil-Smoller, V. Spada, W. Weiss, R. Arnon, I. Jacobsohn, D. Teitelbaum, and M. Sela. 1987. A pilot trial of copolymer 1 in exacerbating-remitting multiple sclerosis. N. Engl. J. Med. 317:408.
24. Johnson, K. P., B. R. Brooks, J. A. Cohen, C. C. Ford, J. Goldstein, R. P. Lisak, L. W. Myers, H. S. Panitch, J. W. Rose, R. B. Schiffer, T. Vollmer, L. P. Weiner, J. S. Wolinsky, and The Copolymer 1 Multiple Sclerosis Study Group. 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Neurology 45:1268.
25. Aharoni, R., D. Teitelbaum, and R. Arnon. 1993. T suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis. Eur. J. Immunol. 23:17.
26. Teitelbaum, D., R. Aharoni, R. Arnon, and M. Sela. 1988. Specific inhibition of the T-cell response to myelin basic protein by synthetic copolymer 1. Proc. Natl. Acatl. Sci. USA 85:9724.
27. Teitelbaum, D., R. Milo, R. Arnon, and M. Sela. 1992. Synthetic copolymer 1 inhibits human T cell lines specific for myelin basic protein. Prof. Natl. Acad. Sci. USA 89:137.
28. Fridkis-Hareli, M., D. Teitelbaum, E. Gurevich, I. Pecht, C. Brautbar, O. J. Kwon, T. Brenner, R. Arnon, and M. Sela. 1994. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells: specificity and promiscuity. Proc. Natl. Acad. Sci. USA 91:4872.
29. Teitelbaum, D., M. Fridkis-Hareli, R. Arnon, and M. Sela. 1996. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64:209.
30. Fridkis-Hareli, M., D. Teitelbaum, N. Kerlero de Rosbo, R. Arnon, and M. Sela. 1994. Synthetic copolymer 1 inhibits the binding of MBP, PLP and MOG peptides to class 11 major histocompatibility complex molecules on antigen-presenting cells. J. Neurochem. 63(Suppl. 1):S61.
31. Fridkis-Hareli, M., D. Teitelbaum, R. Arnon, and M. Sela. 1995. Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells. Cell. Immunol. 163:229.
32. Gorga, J. C., P. J. Knudsen, J. A. Foran, J. L. Strominger, and S. J. Burakoff. 1986. Immunochemically purified DR antigens in liposomes stimulate xenogeneic cytolytic T cells in secondary in vitro cultures. Cell. Immunol. 103:160.
33. Gorga, J. C. V. Horejsi, D. R. Johnson, R. Raghupathy, and J. L. Strominger. 1987. Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line. J. Biol. Chem. 262:16087.
34. Barany, G., and R. Merrifield. 1979. The Peptides. E. Gross and J. Meinhofer, eds. Academic Press, New York. p. 1.
35. Stern, L. J., and D. C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty. αβ heterodimers in the absence of antigenic peptide. Cell 68:465.
36. 2 trimers in solution. Proc. Natl. Acad. Sci. USA 92:12156.
37. Roche, P. A., and P. Cresswell. 1990. High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR. J. Immunol. 144:1849.
38. O'Sullivan, D., J. Sidney, E. Appella, L. Walker, L. Phillips, S. M. Colon, C. Miles, R. W. Chesnut, and A. Sette. 1990. Characterization of the specificity of peptide binding to four DR haplotypes. J. Immunol. 145:1799.
39. O'Sullivan, D., J. Sidney, M.-F. Del Guercio, S. M. Colon, and A. Sette. 1991. Truncation analysis of several DR binding epitopes. J. Immunol. 146:1240.
40. Segel, L. A. 1980. Mathematical Models in Molecular and Cellular Biology. Cambridge University Press, Cambridge, p. 16.
41. Jensen, P. E. 1990. Regulation of antigen presentation by acidic pH. J. Exp. Med. 171:1779.
42. Jensen, P. E. 1992. Long-lived complexes between peptide and class II MHC are formed at low pH with no requirement for pH neutralization. J. Exp. Med. 176: 793.
43. Runnels, H. A., J. C. Moore, and P. E. Jensen. 1996. A structural transition in class II major histocompatibility complex proteins at mildly acidic pH. J. Exp. Med. 183:127.
44. Babbitt, B. P., P. M. Allen, G. Matsueda, E. Haber, and E. R. Unanue. 1985. Binding of immunogenic peptides to Ia histocompatibility molecules. Nature 317:359.
45. Sette, A., S. Southwood, D. O'Sullivan, F. C. A. Gaeta, J. Sidney, and H. M. Grey. 1992. Effect of pH on MHC class II-peptide interactions. J. Immunol. 148:844.
46. Mouritsen, S., A. S. Hansen, B. L. Petersen, and S. Buus. 1992. pH dependence of the interaction between immunogenic peptides and MHC class II molecules: evidence for an acidic intracellular compartment being the organelle of interaction. J. Immunol. 148:1438.
47. Buus, S., A. Sette, S. M. Colon, C. Miles, and H. M. Grey. 1986. Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell 47:1071.
48. Jensen, P. E. 1991. Enhanced binding to peptide antigen to purified class II major histocompatibility glycoproteins at acidic pH. J. Exp. Med. 174:1111.
49. Zisman, E., M. Sela, and E. Mozes. 1991. Direct binding of a synthetic multichain polypeptide to class II major histocompatibility complex molecules on antigen-presenting cells and stimulation of a specific T-cell line require processing of the polypeptide. Proc. Natl. Acad. Sci. USA 88.-9738.
50. Jardetzky, T. S., J. H. Brown, J. C. Gorga, L. J. Stern, R. G. Urban, Y. I. Chi, C. Stauffacher, J. L. Strominger, and D. C. Wiley. 1994. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 368:711.
51. Kim, J., R. G. Urban, J. L. Strominger, and D. C. Wiley. 1994. Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1. Science 266:1870.
52. Abrahmsen, L., M. Dohlsten, S. Segren, P. Bjork, E. Jonsson, and T-Kalland. 1995. Characterization of two distinct MHC class II binding sites in the super-antigen staphylococcal enterotoxin A. EMBO J. 14:2978.
53. Hudson, K. R., R. E. Tiedemann, R. G. Urban, S. C. Lowe, J. L. Strominger, and J. D. Fraser. 1995. Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II. J. Exp. Med. 182:711.
54. Thibodeau, J., I. Cloutier, P. M. Lavoie, N. Labrecque, W. Mourad, T. S. Jardetzky, and R. P. Sekaly. 1994. Subsets of HLA-DR1 molecule defined by SEB and TSST-1 binding. Science 266:1874.
55. Hammer, J., P. Valsasnini, K. Tolba, D. Bolin, J. Higelin, B. Takacs, and F. Sinigaglia. 1993. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74:197.
56. Roof, R. W., I. F. Luescher, and E. R. Unanue. 1990. Phospholipids enhance the binding of peptides to class II major histocompatibility molecules. Proc. Natl. Acad. Sci. USA 87:1735.
57. Sinigaglia, F., and J. Hammer. 1995. Motifs and supermotifs for MHC class II binding peptides. J. Exp. Med. 181:449.
58. Sette, A., S. Southwood, J. Miller, and E. Appella. 1995. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J. Exp. Med. 181:677.
59. Malcherek, G., V. Gnau, G. Jung, H.-G. Rammensee, and A. Melms. 1995. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex class II molecules. J. Exp. Med. 181:527.
60. Panina-Bordignon, P., A. Tan, A. Termijielen, S. Demotz, G. Corradin, and A. Lanzavecchia. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:2237.
61. Sette, A., S. Buus, S. Colon, C. Miles, and H. M. Grey. 1989. Structural analysis of peptides capable of binding to more than one Ia antigen. J. Immunol. 142:35.
62. Busch, R., G. Strang, K. Howland, and J. B. Rothbard. 1990. Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces. Int. Immunol. 2:443.
63. Avva, R. R., and P. Cresswell. 1994. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity 1:763.
64. Kropshofer, H., A. B. Vogt, L. J. Stern, and G. J. Hammerling. 1995. Self-release of CLIP in peptide loading of HLA-DR molecules. Science 270:1357.
65. Sloan, V. S., P. Cameron, G. Porter, M. Gammon, M. Amaya, E. Mellins, and D. M. Zaller. 1995. Mediation by HLA-DM of dissociation of peptides trom HLA-DR. Nature 375:802.
66. Tompkins, S. M., J. C. Moore, and P. Jensen. 1996. An insulin peptide that binds an alternative site in class II major histocompatibility complex. J. Exp. Med. 183:857.
67. Hammer, J., B. Takacs, and F. Sinigaglia. 1992. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J. Exp. Med. 176:1007.
68. Hammer, J., P. Valsasnini, K. Tolba, D. Bolin, J. Higelin, B. Takacs, and F. Sinigaglia. 1993. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74:197.
69. Sette, A., J. Sidney, C. Oseroff, M. F. Del Guercio, S. Southwood, T. Arrhenius, M. F. Powell, S. Colon, F. C. A. Gaeta, and H. M. Grey. 1993. HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J. Immunol. 151:3163.
70. Vogt, A. B. H. Kropshofer, H. Kalbacher, M. Kalbus, H.-G. Rammensee, J. E. Coligan, and R. Martin. 1994. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J. Immunol. 153:1665.
71. Wucherpfennig, K. W., A. Sette, S. Southwood, C. Oseroff, M. Matsui, J. L. Strominger, and D. A. Hafler. 1994. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J. Exp. Med. 179:279.